A five-peptide cancer vaccine induced tumor-specific killer T-cells that infiltrated esophageal tumors in all 15 patients, while upregulating PD-1/PD-L1 — suggesting synergy with checkpoint immunotherapy.
100% CTL responseAll 15 patients developed cytotoxic T-lymphocyte responses to at least one of the five vaccine peptides, and the same T-cell receptors were confirmed in both blood and tumor tissue
What the researchers found
The cancer peptide vaccine S-588410 — containing five HLA-A*24:02-restricted peptides derived from cancer testis antigens — successfully induced tumor-specific immune responses in all 15 esophageal cancer patients. After vaccination, tumor tissue showed increased densities of CD8+ T-cells, CD8+ granzyme B+ cells (indicating active killing), and CD8+ PD-1+ cells. PD-L1 expression also increased in the tumor microenvironment.
Critically, the same peptide-specific T-cell receptor sequences were found in both blood and tumor tissue after vaccination, confirming that the vaccine-induced killer T-cells actually infiltrated the tumors. The upregulation of PD-1 and PD-L1 after vaccination suggests that combining S-588410 with checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) could further enhance its anti-cancer effect.
Why it matters
Cancer peptide vaccines have long been pursued as a way to train the immune system to specifically target cancer cells. This study provides direct evidence that a peptide vaccine can successfully drive tumor-infiltrating lymphocytes into esophageal tumors — and reveals that the resulting immune response upregulates PD-1/PD-L1, providing a biological rationale for combining peptide vaccines with immune checkpoint inhibitors. This combination strategy could make both therapies more effective.
The numbers in context
n=15 patients · 5-peptide vaccine · Median 5 doses · CTL response in 100% for ≥1 peptide · 80% had treatment-related AEs · Injection site reactions: grade 1 (n=1), grade 2 (n=11)
How the study worked
This was an exploratory open-label clinical study in 15 HLA-A*24:02-positive esophageal cancer patients. S-588410 was administered subcutaneously emulsified with MONTANIDE ISA51VG adjuvant (median 5 doses). Researchers analyzed pre- and post-vaccination tumor tissue for immune cell densities (CD8+, granzyme B+, PD-1+, PD-L1+) using immunohistochemistry. CTL responses were assessed in blood, and peptide-specific T-cell receptor sequencing was performed on both tumor tissue and blood samples.
Who was studied
15 HLA-A*24:02-positive esophageal cancer patients
What this study cannot tell us
This is an open-label exploratory study with only 15 patients and no control group, making it impossible to attribute clinical benefit to the vaccine. The study focused on immunological endpoints rather than tumor response or survival. Only HLA-A*24:02-positive patients were eligible, limiting applicability. The MONTANIDE adjuvant may contribute to the high rate of injection site reactions.
How to read the evidence
This is a small exploratory open-label clinical study (n=15) without a control group, designed to investigate immunological mechanisms rather than clinical efficacy. While the immunological findings are compelling, the evidence is preliminary and cannot demonstrate clinical benefit.
When this study was published
Published in 2020, this study represents an important proof-of-concept for cancer peptide vaccines in esophageal cancer. Subsequent combination studies with checkpoint inhibitors may have been initiated based on these findings.
The bigger picture
Cancer peptide vaccines have been studied for decades with mixed clinical results. A key challenge has been proving that vaccine-induced T-cells actually reach and infiltrate tumors. This study provides that proof through T-cell receptor sequencing — showing the same vaccine-specific T-cells in both blood and tumor tissue. The PD-1/PD-L1 finding is particularly significant because it suggests why peptide vaccines alone have had limited success: the tumors mount a counter-defense through checkpoint pathways. Combining vaccines with checkpoint inhibitors could overcome this barrier, representing a new paradigm in cancer immunotherapy.
Questions still open
- Will combining S-588410 with anti-PD-1/PD-L1 checkpoint inhibitors produce measurable tumor responses in esophageal cancer?
- Can similar multi-peptide vaccine approaches be developed for other HLA types to expand eligibility beyond A*24:02 patients?
- Does the degree of tumor-infiltrating lymphocyte increase after vaccination correlate with clinical outcomes?
Common questions
How does a cancer peptide vaccine work?
Why might combining this vaccine with checkpoint inhibitors work better?
Read the original research
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
Cancer immunology, immunotherapy : CII, 69(11), 2247-2257
Citation
Daiko, H; Marafioti, T; Fujiwara, T; Shirakawa, Y; Nakatsura, T; Kato, K; Puccio, I; Hikichi, T; Yoshimura, S; Nakagawa, T; Furukawa, M; Stoeber, K; Nagira, M; Ide, N; Kojima, T. (2020). Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.. Cancer immunology, immunotherapy : CII, 69(11), 2247-2257. https://doi.org/10.1007/s00262-020-02619-3